

**Invitrocue Appoints Dr. Andreas Lindner as CEO of Europe
and Professor David Waugh as Senior Advisor**

November 19, 2018 – Invitrocue Limited (ASX: IVQ), a leading healthcare bio-analytic solutions provider, is pleased to announce the appointment of Dr. Andreas Lindner as CEO of Europe and Professor David Waugh as Senior Advisor with immediate effect.

Appointed in February 2018 as Invitrocue's Non-Executive Director, Dr. Andreas Lindner has been overseeing Invitrocue's business direction and providing strategic counsel to the management team. In his new role, Andreas will be responsible for establishing Invitrocue's commercial operations in Europe, focusing on the successful roll-out of the company's proprietary Onco-PDO™ personalised cancer screening technology. Earlier in 2018, Invitrocue secured a grant to support its European launch plans from Invest Northern Ireland. Invitrocue has since incorporated new operating entities in the United Kingdom and Germany and is establishing a European reference laboratory in Germany as it prepares to commercialise Onco-PDO™ in Europe.

Professor David Waugh is currently the Professor and Head of School, School of Biomedical Sciences at Queensland University of Technology. He was most recently the Director of the Centre for Cancer Research and Cell Biology (CCRCB) at Queen's University Belfast and Professor of Molecular Oncology and Therapeutics, with a primary research interest in understanding how inflammatory signals contribute to the initiation and progression of prostate cancers. Prof. Waugh has published more than 100 articles and has participated in various research projects including clinical trials in the treatment of solid tumours and prostate cancer progression. Aligned with his current research focus, Prof. Waugh will provide guidance on prostate cancer as a Senior Advisor to Invitrocue.

Commenting on the appointments, Dr. Steven Fang, Chief Executive Director, Invitrocue, said:

"I'm delighted to welcome both Dr. Lindner and Prof. Waugh to Invitrocue. Their respective market experience and scientific / clinical experiences will help in our commercial endeavours in Personalised Oncology with Onco-PDO

Invitrocue has benefited greatly from the guidance that Dr. Lindner provided in his capacity as a Non-Executive Director. As we establish our new laboratory facilities in Germany and operations in key European markets, Dr. Lindner's track record in building successful healthcare businesses and implementing commercialisation strategies will put us in a strong position to build a leading commercial operation in Europe.

Prof. Waugh brings decades of experience to Invitrocue and we look forward to the valuable insight and guidance that he will provide to our research team. His specific insight into the Australian healthcare market will be important as we look to make the Onco-PDO™ service available there. Working together, Invitrocue will be able explore more tumor profiles where Onco-PDO™ could transform drug sensitivity tests and help physicians to develop personalised treatment plans for cancer patients worldwide."

-ENDS-

For more information contact:

Martin D. Bach, VP Operations

T: +65 6460 0497

martind.bach@invitrocue.com

About Invitrocue

Invitrocue is a leading healthcare bio-analytic solutions provider including in vitro cell-based testing technologies and image analytics software for use in digital pathology. Invitrocue has developed a unique 3D cell-based scaffolding technology that mimics human organ samples for using in the field of infectious diseases. In 2016, the company expanded its work in liver disease to the field of oncology. Invitrocue's Onco-PDO™ technology enables patient-derived cancer cells (organoids) to be cultured in laboratories for testing against a panel of drugs to support clinical decision making for individual patients (personalised medicine).

Invitrocue's technology originated in Singapore's Agency for Science, Technology and Research (A*STAR). Invitrocue has been developed and validated in partnerships with leading biopharmaceutical companies and scientific collaborators.

Invitrocue is listed on the Australian Securities Exchange under the ticker IVQ. Website: www.invitrocue.com